SNS Financial Group LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,211 shares of the medical research company’s stock after selling 202 shares during the quarter. SNS Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $272,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Capital Investment Advisory Services LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $35,000. Gradient Investments LLC raised its stake in shares of Thermo Fisher Scientific by 1,887.5% during the 4th quarter. Gradient Investments LLC now owns 159 shares of the medical research company’s stock worth $36,000 after purchasing an additional 151 shares in the last quarter. Exane Derivatives bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $39,000. Signet Investment Advisory Group Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $40,000. Finally, IMS Capital Management bought a new stake in Thermo Fisher Scientific in the 3rd quarter valued at $53,000. Institutional investors own 91.80% of the company’s stock.

A number of research analysts have commented on the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Friday, November 30th. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 30th. BTIG Research upped their price objective on Thermo Fisher Scientific to $290.00 and gave the stock a “buy” rating in a research report on Thursday, January 31st. Finally, Morgan Stanley increased their target price on Thermo Fisher Scientific from $254.00 to $260.00 and gave the company an “overweight” rating in a research report on Thursday, October 25th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $275.70.

NYSE TMO opened at $252.49 on Friday. Thermo Fisher Scientific Inc. has a one year low of $199.85 and a one year high of $253.91. The company has a market cap of $101.65 billion, a P/E ratio of 22.71, a price-to-earnings-growth ratio of 1.63 and a beta of 1.14. The company has a quick ratio of 1.23, a current ratio of 1.71 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.26 billion. During the same quarter last year, the firm posted $2.79 earnings per share. The firm’s revenue was up 7.6% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 12.14 EPS for the current fiscal year.

In other Thermo Fisher Scientific news, Director Tyler Jacks sold 1,100 shares of the firm’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $251.98, for a total value of $277,178.00. Following the completion of the sale, the director now owns 5,879 shares of the company’s stock, valued at $1,481,390.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gregory J. Herrema sold 17,235 shares of the firm’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $247.00, for a total value of $4,257,045.00. Following the completion of the sale, the insider now directly owns 26,446 shares of the company’s stock, valued at approximately $6,532,162. The disclosure for this sale can be found here. Insiders sold 32,607 shares of company stock valued at $7,972,085 in the last three months. Insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/sns-financial-group-llc-has-272000-stake-in-thermo-fisher-scientific-inc-tmo/2826232.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Investing in Dividend Stocks

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.